Tenet Reports Second Quarter 2022 Results; Reaffirms 2022 Adjusted EBITDA Outlook

  • Net income from continuing operations available to common shareholders in Q2'22 of $38 million versus $120 million in Q2'21
  • Consolidated Adjusted EBITDA in Q2'22 of $843 million versus $834 million in Q2'21
  • Q2'22 USPI Adjusted EBITDA grew 15.3 percent over Q2'21 excluding grant income; Same-facility system-wide ambulatory surgical cases decreased 0.9 percent versus Q2'21 due to the pandemic
  • Diluted earnings per share from continuing operations available to common shareholders in Q2'22 of $0.35 compared to $1.11 in Q2'21; Adjusted diluted earnings per share from continuing operations of $1.50 in Q2'22 compared to $1.59 in Q2'21
  • The disruptive cybersecurity incident contributed to same-hospital adjusted admissions for Q2'22 decreasing 5.3 percent versus Q2'21
  • Effective June 30, 2022, Tenet now owns 100% of USPI's voting stock, having acquired the remaining 5% ownership interest for $406 million
  • Refinanced ~$1.75 billion of 6.75% senior unsecured notes due 2023 with new 6.125% senior secured notes due 2030; the Company has no significant debt maturities until July 2024
  • FY 2022 Adjusted EBITDA Outlook reaffirmed at $3.375 billion to $3.575 billion

Tenet Healthcare Corporation (Tenet) THC today announced its results for the quarter ended June 30, 2022 (Q2'22). Tenet's results for Q2'22 versus the quarter ended June 30, 2021 (Q2'21) are as follows:

($ in millions, except per share results)

Q2'22

Q2'21

YTD Q2'22

YTD Q2'21

Net income available to Tenet common shareholders from continuing operations

$38

$120

$177

$217

Net income available to Tenet common shareholders from continuing operations per diluted share

$0.35

$1.11

$1.63

$2.00

Adjusted EBITDA excluding grant income

$749

$810

$1,631

$1,550

Adjusted EBITDA including grant income

$843

$834

$1,731

$1,611

Adjusted diluted earnings per share from continuing operations

$1.50

$1.59

$3.38

$2.89

The table above as well as tables and discussions throughout this earnings release include certain financial measures that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-3 included at the end of this earnings release. Management's reasoning for the use of these non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.

"We had another strong quarter and are reaffirming our 2022 Adjusted EBITDA Outlook," said Saum Sutaria, M.D., Chief Executive Officer of Tenet. "We demonstrated resilience in the face of a disruptive cyber attack and discipline through challenging market conditions. The ongoing diversification of Tenet driven by our capital efficient ambulatory expansion is a key differentiator that presents compelling opportunities for growth in earnings and free cash flows."

COVID-19 Pandemic (COVID)

The Company continues to treat COVID patients and effectively manage the operational and financial impact of the pandemic on its operations. COVID admissions were 3 percent of total admissions in Q2'22 compared to 12 percent of total admissions in Q1'22.

Results from Continuing Operations Available to Tenet Common Shareholders

  • Net income from continuing operations available to the Company's common shareholders in Q2'22 was $38 million, or $0.35 per diluted share, versus $120 million, or $1.11 per diluted share, in Q2'21.
  • For YTD Q2'22, net income from continuing operations available to the Company's common shareholders was $177 million, or $1.63 per diluted share, compared to $217 million, or $2.00 per diluted share, for YTD Q2'21.

Adjusted Net Income from Continuing Operations Available to Tenet Common Shareholders

Reconciliations of net income available to Tenet common shareholders to Adjusted net income from continuing operations available to Tenet common shareholders are contained in Table #1 at the end of this release.

  • Tenet's Q2'22 Adjusted net income from continuing operations available to its common shareholders was $163 million, or $1.50 per diluted share, compared to $173 million, or $1.59 per diluted share, in Q2'21.
  • Tenet's YTD Q2'22 Adjusted net income from continuing operations available to its common shareholders was $376 million, or $3.38 per diluted share, compared to $313 million, or $2.89 per diluted share, in YTD Q2'21.
  • The change in the interest expense limitation regulations beginning in 2022 resulted in approximately $20 million of additional income tax expense in Q2'22 and $39 million YTD Q2'22, or $0.18 and $0.34 per diluted share, respectively, compared to the corresponding 2021 periods.

Adjusted EBITDA

Reconciliations of net income available to Tenet common shareholders to Adjusted EBITDA are contained in Table #2 at the end of this release.

  • Adjusted EBITDA in Q2'22 was $843 million compared to $834 million in Q2'21.
  • For YTD Q2'22, Adjusted EBITDA was $1.731 billion compared to $1.611 billion in YTD Q2'21.

Cybersecurity Incident

  • In April 2022, Tenet experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations. During this time, the Company's hospitals remained operational and continued to deliver patient care safely and effectively, utilizing well-established back‑up processes. The Company immediately suspended user access to impacted information technology applications, executed extensive cybersecurity protection protocols, and took steps to restrict further unauthorized activity.
  • Tenet has fully restored impacted information technology operations. The Company estimates that this incident had an unfavorable impact of approximately $100 million to Adjusted EBITDA during Q2'22. The Company has insurance coverage and filed a claim that is within its policy limits, which is ongoing. $5 million of insurance proceeds were received during Q2'22.

Acquires remainder of USPI

  • On June 30, 2022, the Company acquired Baylor University Medical Center's entire 5% ownership interest in our USPI business for $406 million. The Company now owns 100% of the voting stock of USPI. Under the terms of the transaction, Tenet will pay approximately $11 million per month over the next three years on an interest-free basis. The first payment was made in Q2'22.

Financing Activities

  • In June 2022, the Company completed a private placement of $2.000 billion in aggregate principal amount of newly issued 6.125 percent senior secured first lien notes maturing in 2030. The Company used the net proceeds from the sale of the notes, after payment of fees and expenses, to finance the redemption of all $1.748 billion aggregate principal amount then outstanding of its 6.75 percent senior unsecured notes due 2023.
  • In Q1'22, the Company retired $700 million aggregate principal amount of its 7.50 percent senior secured notes due in 2025, for a total redemption price of approximately $730 million, using available cash on hand. In the first half of 2022, the Company purchased approximately $124 million aggregate principal amount of its 6.75 percent senior unsecured notes due in 2023 on the open market for approximately $129 million using available cash on hand ($103 million of which was purchased in Q1'22). In conjunction with these transactions, the Company's future annual cash interest payments will be reduced by $61 million.

Ambulatory Care (Ambulatory) Segment Results

Tenet's Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of June 30, 2022, USPI had interests in 410 ambulatory surgery centers (261 consolidated) and 24 surgical hospitals (eight consolidated) in 34 states. Results for YTD Q2'21 included USPI's imaging centers (realigned under the Hospital segment as of April 1, 2021) and its urgent care centers (sold in April 2021). For all periods presented, the Company owned 95 percent of the voting stock of USPI.

Ambulatory segment results ($ in millions)

Q2'22

Q2'21

YTD Q2'22

YTD Q2'21

Revenues

 

 

 

 

Net operating revenues

$771

$664

$1,509

$1,310

Grant income excluding amount in equity earnings

$2

$15

$4

$22

Grant income in equity earnings

$—

$5

$—

$11

Same-facility system-wide net patient service revenues (a)

$1,503

$1,462

$2,942

$2,780

Volume Changes versus the Prior-Year Period

 

 

 

 

Same-facility system-wide surgical cases (a)

(0.9) %

68.2 %

3.3 %

29.1 %

Same-facility system-wide surgical cases on same-business day basis (a)

(0.9) %

68.2 %

2.4 %

30.1 %

Adjusted EBITDA, Margins and Noncontrolling Interest (NCI)

 

 

 

 

Adjusted EBITDA excluding grant income

$317

$275

$597

$519

Adjusted EBITDA including grant income

$319

$295

$601

$552

Adjusted EBITDA margin excluding grant income

41.1 %

41.4 %

39.6 %

39.6 %

Adjusted EBITDA margin including grant income

41.4 %

44.4 %

39.8 %

42.1 %

Adjusted EBITDA less facility-level NCI excluding grant income

$209

$176

$395

$336

Adjusted EBITDA less facility-level NCI

$210

$187

$397

$356

Adjusted EBITDA less total NCI excluding grant income

$204

$172

$386

$328

Adjusted EBITDA less total NCI

$205

$182

$388

$347

(a)

Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment's results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.

Revenues and Volumes

  • The Ambulatory segment produced net operating revenues of $771 million in Q2'22, an increase of 16.1 percent compared to $664 million in Q2'21. This increase primarily related to service line growth and additional revenues associated with the SurgCenter Development (SCD) acquisition completed in December 2021 and improved pricing yield, partially offset by the absence of revenues from USPI's urgent care centers, which were sold in the second quarter of 2021.
  • Surgical business same-facility system-wide net operating revenues increased 2.8 percent in Q2'22 compared to Q2'21, with cases down 0.9 percent and net revenue per case up 3.7 percent.

Adjusted EBITDA

  • Ambulatory segment Adjusted EBITDA was $319 million in Q2'22 ($317 million excluding $2 million of grant income) compared to $295 million in Q2'21 ($275 million excluding $20 million of grant income), driven by the SCD acquisition, as well as new service line growth and improved pricing yield.
  • Adjusted EBITDA margin for the Ambulatory segment was 41.4 percent in Q2'22 (41.1 percent excluding grant income) compared to 44.4 percent in Q2'21 (41.4 percent excluding grant income).
  • Adjusted EBITDA less facility-level NCI in Q2'22 was $210 million ($209 million excluding grant income) compared to $187 million in Q2'21 ($176 million excluding grant income).

Hospital Operations and Other (Hospital) Segment Results

Tenet's Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. Effective April 1, 2021, the Company's imaging centers that were previously operated under USPI were realigned under the Hospital segment.

Hospital segment results ($ in millions)

Q2'22

Q2'21

YTD Q2'22

YTD Q2'21

Revenues

 

 

 

 

Net operating revenues (prior to inter-segment eliminations)

$3,645

$4,095

$7,443

$8,042

Grant income

$92

$4

$96

$28

Same-hospital net patient service revenues (b)

$3,314

$3,507

$6,792

$6,899

Same-Hospital Volume Changes versus the Prior-Year Period (b)

 

 

 

 

Admissions

(8.1) %

13.8 %

(6.4) %

0.4 %

Adjusted admissions (c)

(5.3) %

23.6 %

(3.5) %

2.6 %

Outpatient visits (including outpatient ER visits)

(10.0) %

71.1 %

(4.7) %

19.7 %

Emergency Room visits (inpatient and outpatient)

3.8 %

35.2 %

8.5 %

(2.1) %

Hospital surgeries

(8.0) %

36.5 %

(4.3) %

13.1 %

Adjusted EBITDA

 

 

 

 

Adjusted EBITDA excluding grant income

$339

$445

$849

$855

Adjusted EBITDA including grant income

$431

$449

$945

$883

Adjusted EBITDA margin

 

 

 

 

Adjusted EBITDA margin excluding grant income

9.3 %

10.9 %

11.4 %

10.6 %

Adjusted EBITDA margin including grant income

11.8 %

11.0 %

12.7 %

11.0 %

(b)

Same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company's Hospital segment continuously from January 1, 2020 through June 30, 2022. Amounts associated with physician practices are excluded. Prior-period same-hospital net patient service revenues and volume changes have been recast to reflect only the continuously operated facilities since January 1, 2020.

(c)

Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.

Revenues and Volumes

  • Net operating revenues (which exclude grant income) in the Hospital segment were $3.645 billion in Q2'22, a decline of 11.0 percent from $4.095 billion in Q2'21. The decrease in revenues was primarily due to the sale of the Company's Miami-area hospitals in Q3'21 and the unfavorable impact of the cybersecurity incident, partially offset by improved pricing yield.
  • Same-hospital net patient service revenue per adjusted admission decreased 0.2 percent year-over-year for Q2'22 primarily due to the unfavorable impact of the cybersecurity incident, partially offset by improved pricing yield.

Adjusted EBITDA

  • Adjusted EBITDA in the segment was $431 million in Q2'22 ($339 million excluding $92 million of grant income) compared to $449 million in Q2'21 ($445 million excluding $4 million of grant income).
  • Adjusted EBITDA in Q2'22 included an approximate $100 million unfavorable impact related to the cybersecurity incident.
  • The Adjusted EBITDA margin excluding grant income was 9.3 percent in Q2'22 compared to 10.9 percent in Q2'21 reflecting the adverse impact from the cybersecurity incident, higher contract labor rates and premium pay due to the pandemic, partially offset by continued strength in patient acuity due to the Company's focus on growing higher acuity services, improved pricing yield and cost efficiency actions.

Conifer Segment Results

Tenet's Conifer business segment provides comprehensive end-to-end and focused-point business process services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions to hospitals, health systems, physician practices, employers and other clients.

Conifer segment results ($ in millions)

Q2'22

Q2'21

YTD Q2'22

YTD Q2'21

Net operating revenues

$333

$319

$657

$629

Adjusted EBITDA

$93

$90

$185

$176

Adjusted EBITDA margin

27.9 %

28.2 %

28.2 %

28.0 %

Revenues

Conifer segment revenues in Q2'22 were $333 million compared to $319 million in Q2'21, an increase of 4.4 percent, primarily due to contractual rate increases and new business expansion. Revenues from external clients in Q2'22 were $222 million compared to $195 million in Q2'21, an increase of 13.8 percent.

Adjusted EBITDA

Conifer generated $93 million of Adjusted EBITDA in Q2'22 compared to $90 million in Q2'21 primarily due to the impact of 4.4 percent revenue growth and continued effective cost management. Conifer's Adjusted EBITDA margin was 27.9 percent in Q2'22 versus 28.2 percent in Q2'21.

Balance Sheet, Cash Flows and Liquidity

Balance Sheet Highlights

($ in millions)

June 30,
2022

March 31,
2022

December 31,
2021

Cash and cash equivalents

$1,351

$1,405

$2,364

Accounts receivable days outstanding

59.8

58.9

57.0

Line-of-credit borrowings outstanding

Ratio of net debt plus Medicare advances liability to Adjusted EBITDA (d)

3.92

3.93

4.07

(d)

Net debt is total debt less cash and cash equivalents

  • Cash and cash equivalents at June 30, 2022 were $1.013 billion lower than December 31, 2021 primarily due to the Company's early retirement of $824 million of debt.
  • In the year ended December 31, 2020 (FY 2020), the Company received approximately $1.5 billion of Medicare advance payments from CMS related to the pandemic. Approximately $475 million of the Medicare advances were repaid in the YTD Q2'22 period by the Company, and approximately $616 million of these advances were repaid by the Company during the year ended December 31, 2021. Repayment terms for the Medicare advance payments began in April 2021 (12 months from the Company's receipt of the advance payments in April 2020). An annual interest rate of 4.0 percent will be assessed on any outstanding balances 29 months from the initial advance. The Company began repaying these advance payments in April 2021 and expects to substantially repay the advances by the end of Q3'22.
  • The Company had no outstanding borrowings on its $1.5 billion line of credit as of June 30, 2022.
  • The Company's ratio of net debt plus the Medicare advances liability to Adjusted EBITDA was 3.92x at June 30, 2022 compared to 3.93x at March 31, 2022 and 4.07x at December 31, 2021.
  • Accounts receivable days outstanding increased to 59.8 days at June 30, 2022 compared to 57.0 days at December 31, 2021. This change is due in part to the cybersecurity incident and the approval of Texas' Medicaid supplemental funding programs by CMS at the end of March 2022, which resulted in the Company recognizing revenue beginning in March 2022 that has not been fully collected yet since the program was just recently approved.

Cash flows and liquidity

Reconciliations of net cash provided by operating activities to both Free Cash Flow and Adjusted Free Cash Flow are contained in Table #3 at the end of this release.

($ in millions)

Q2'22

Q2'21

YTD Q2'22

YTD Q2'21

Net cash provided by operating activities

$119

$245

$347

$779

Capital expenditures

($152)

($122)

($307)

($243)

Free cash flow

($33)

$123

$40

$536

Adjusted free cash flow

$9

$157

$138

$621

Net cash used in investing activities

($140)

($50)

($200)

($195)

Net cash used in financing activities

($33)

($142)

($1,160)

($836)

  • The Company produced free cash flow of $(33) million in Q2'22 ($248 million excluding $281 million of repayments in Q2'22 associated with Medicare advances). There were $152 million repayments of Medicare advances in Q2'21.
  • The Company produced free cash flow of $40 million in YTD Q2'22 ($515 million excluding $475 million of repayments in YTD Q2'22 associated with Medicare advances). There were no repayments of Medicare advances in Q1'21 and $152 million repayments of Medicare advances in Q2'21.
  • Also, free cash flow in YTD Q2'22 included $104 million of pandemic-related grant receipts compared to $36 million in YTD Q2'21.

Company Outlook

  • Reconciliations of Outlook net income available to Tenet common shareholders to Outlook Adjusted EBITDA for the year ending December 31, 2022 (FY 2022) and the quarter ending September 30, 2022 (Q3'22) are contained in Table #4 at the end of this release.
  • Reconciliations of Outlook net income available to Tenet common shareholders to Outlook Adjusted net income from continuing operations to common shareholders for FY 2022 and Q3'22 are contained in Table #5 at the end of this release.
  • Reconciliations of Outlook net cash provided by operating activities to Outlook free cash flow and Outlook Adjusted free cash flow from continuing operations for FY 2022 are contained in Table #6 at the end of this release.

Tenet's Outlook for FY 2022 (consolidated and by segment) and Q3'22 follows:

CONSOLIDATED ($ in millions except per share amounts)

FY 2022 Outlook

Q3'22 Outlook

Net operating revenues

$19,000 to $19,400

$4,700 to $4,900

Income from continuing operations available to Tenet common stockholders

$371 to $546

$100 to $135

Adjusted EBITDA

$3,375 to $3,575

$775 to $825

Adjusted EBITDA margin

17.8% to 18.4%

16.5% to 16.8%

Diluted income per common share from continuing operations

$3.35 to $4.91

$0.91 to $1.23

Adjusted net income from continuing operations

$645 to $780

$125 to $150

Adjusted diluted earnings per share from continuing operations

$5.80 to $7.00

$1.14 to $1.36

Equity in earnings of unconsolidated affiliates

$230 to $250

$55 to $65

Depreciation and amortization

$840 to $860

$205 to $215

Interest expense

$880 to $890

$215 to $225

Net income available to NCI

$590 to $630

$125 to $145

Weighted average diluted common shares

~112 million

~110 million

NCI cash distributions

$550 to $590

 

Effective tax rate (e)

~24%

 

Net cash provided by operating activities

$1,100 to $1,400

 

Adjusted net cash provided by operating activities

$1,300 to $1,550

 

Capital expenditures

$725 to $775

 

Free cash flow

$375 to $625

 

Free cash flow excluding repayments of Medicare Advance Payments and Deferred Payroll Tax Payments

$1,383 to $1,633

 

Adjusted free cash flow – continuing operations

$575 to $775

 

Adjusted free cash flow – continuing operations, excluding repayments of Medicare Advance Payments and Deferred Payroll Tax Payments

$1,583 to $1,783

 

(e)

The effective tax rate is calculated as income tax expense divided by the adjusted pretax income. Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: adjusted pretax income less GAAP facility level NCI expense plus permanent differences, and non-deductible interest expense.

Ambulatory Segment ($ in millions)

FY 2022 Outlook

Net operating revenues

$3,275 to $3,375

Adjusted EBITDA

$1,375 to $1,425

Total NCI (Facility level and Baylor University Medical Center)

$490 to $515

Adjusted EBITDA less total NCI

$885 to $910

Changes versus prior year (f):

 

Surgical cases volumes

Up 3% to 4%

Net revenues per surgical case

Up 2.5% to 3.5%

Hospital Segment ($ in millions)

FY 2022 Outlook

Net operating revenues (prior to inter-segment eliminations)

$14,885 to $15,135

Adjusted EBITDA

$1,640 to $1,780

NCI

$30 to $40

Changes versus prior year (f):

 

Inpatient admissions

(6)% to (4)%

Adjusted admissions

(4)% to (2)%

Conifer Segment ($ in millions)

FY 2022 Outlook

Net operating revenues

$1,325 to $1,375

Adjusted EBITDA

$360 to $370

NCI

$70 to $75

(f)

Same-hospital basis for hospital statistics; USPI surgical cases on a same-facility system-wide basis

Management's Webcast Discussion of Results

Tenet management will discuss the Company's Q2'22 results in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on July 22, 2022. Investors can access the webcast through the Company's website at www.tenethealth.com/investors.

The slide presentation associated with the webcast referenced above, a copy of this earnings press release and a related supplemental financial disclosures document will be available on the Company's Investor Relations website on July 21, 2022.

Cautionary Statement

This release contains "forward-looking statements" - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company's expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "assume," "believe," "budget," "estimate," "forecast," "intend," "plan," "predict," "project," "seek," "see," "target," or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regards to developments related to COVID-19. Particular uncertainties that could cause the Company's actual results to be materially different than those expressed in the Company's forward-looking statements include, but are not limited to, the impact of the COVID-19 pandemic and other factors disclosed under "Forward-Looking Statements" and "Risk Factors" in our Form 10-K for the year ended December 31, 2021, Form 10-Q for the quarter ended March 31, 2022 and other filings with the Securities and Exchange Commission.

About Tenet Healthcare

Tenet Healthcare Corporation THC is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 465 ambulatory surgery centers and surgical hospitals. We also operate 60 acute care and specialty hospitals, approximately 110 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Non-GAAP Financial Measures

  • Adjusted EBITDA, a non-GAAP measure, is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
  • Adjusted diluted earnings (loss) per share from continuing operations, a non-GAAP measure, is defined by the Company as Adjusted net income available (loss attributable) from continuing operations to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.
  • Adjusted net income available (loss attributable) from continuing operations to Tenet common shareholders, a non-GAAP measure, is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses) and (7) the associated impact of these items on taxes and noncontrolling interests. Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
  • Free Cash Flow, a non-GAAP measure, is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment for continuing operations.
  • Free Cash Flow excluding repayments of Medicare Advances and Deferred Payroll Tax Payments, a non-GAAP measure, is defined by the Company as (1) Free Cash Flow plus (2) repayments of Medicare Advances and Deferred Payroll Tax Payments.
  • Adjusted Free Cash Flow, a non-GAAP measure, is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities from continuing operations, less (2) purchases of property and equipment from continuing operations.
  • Adjusted Free Cash Flow excluding repayments of Medicare Advances and Deferred Payroll Tax Payments, a non-GAAP measure, is defined by the Company as (1) Adjusted Free Cash Flow plus (2) repayments of Medicare Advances and Deferred Payroll Tax Payments.
  • Adjusted net cash provided by (used in) operating activities, a non-GAAP measure, is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and (2) net cash provided by (used in) operating activities from discontinued operations.

The Company believes the foregoing non-GAAP measures are useful to investors and analysts because they present additional information on the Company's financial performance. Investors, analysts, Company management and the Company's Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company's financial and operating performance and compare the Company's performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company's Board of Directors also uses certain of these measures to evaluate management's performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company's common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow, and Free Cash Flow and Adjusted Free Cash Flow excluding repayments of Medicare Advances and Deferred Payroll Tax Payments as supplemental non-GAAP measures to analyze cash flows generated from the Company's operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company's financial statements, they do not provide a complete measure of the Company's operating performance. For example, the Company's definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company's Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company's financial performance.

Tenet Healthcare Corporation

Financial Statements and Reconciliations

Q2'22 Earnings Release

 

Table of Contents

 

Description

Page

Consolidated Statements of Operations

14

Consolidated Balance Sheets

16

Consolidated Statements of Cash Flow

17

Segment Reporting

18

Table #1 - Reconciliations of Net Income to Adjusted Net Income

19

Table #2 - Reconciliations of Net Income to Adjusted EBITDA

20

Table #3 - Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow

21

Table #4 - Reconciliations of Outlook Net Income to Outlook Adjusted EBITDA

22

Table #5 - Reconciliations of Outlook Net Income to Outlook Adjusted Net Income

23

Table #6 - Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

24

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

(Dollars in millions except per share amounts)

 

Three Months Ended June 30,

 

 

2022

 

%

 

2021

 

%

 

Change

Net operating revenues

 

$

4,638

 

 

100.0

%

 

$

4,954

 

 

100.0

%

 

(6.4

) %

Grant income

 

 

94

 

 

2.0

%

 

 

19

 

 

0.4

%

 

394.7

%

Equity in earnings of unconsolidated affiliates

 

 

54

 

 

1.2

%

 

 

54

 

 

1.1

%

 

0.0

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

2,126

 

 

45.8

%

 

 

2,280

 

 

46.0

%

 

(6.8

) %

Supplies

 

 

811

 

 

17.5

%

 

 

859

 

 

17.4

%

 

(5.6

) %

Other operating expenses, net

 

 

1,006

 

 

21.7

%

 

 

1,054

 

 

21.3

%

 

(4.6

) %

Depreciation and amortization

 

 

216

 

 

4.7

%

 

 

221

 

 

4.5

%

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

57

 

 

1.2

%

 

 

20

 

 

0.4

%

 

 

Litigation and investigation costs

 

 

18

 

 

0.4

%

 

 

22

 

 

0.4

%

 

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

(1

)

 

%

 

 

(15

)

 

(0.3

) %

 

 

Operating income

 

 

553

 

 

11.9

%

 

 

586

 

 

11.8

%

 

 

Interest expense

 

 

(222

)

 

 

 

 

(235

)

 

 

 

 

Other non-operating expense, net

 

 

 

 

 

 

 

(1

)

 

 

 

 

Loss from early extinguishment of debt

 

 

(66

)

 

 

 

 

(31

)

 

 

 

 

Income from continuing operations, before income taxes

 

 

265

 

 

 

 

 

319

 

 

 

 

 

Income tax expense

 

 

(86

)

 

 

 

 

(61

)

 

 

 

 

Income from continuing operations, before discontinued operations

 

 

179

 

 

 

 

 

258

 

 

 

 

 

Discontinued operations:

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

 

 

 

 

 

(1

)

 

 

 

 

Loss from discontinued operations

 

 

 

 

 

 

 

(1

)

 

 

 

 

Net income

 

 

179

 

 

 

 

 

257

 

 

 

 

 

Less: Net income available to noncontrolling interests

 

 

141

 

 

 

 

 

138

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

38

 

 

 

 

$

119

 

 

 

 

 

Amounts available to Tenet Healthcare Corporation common shareholders

 

 

 

 

 

 

 

 

 

 

Income from continuing operations, net of tax

 

$

38

 

 

 

 

$

120

 

 

 

 

 

Loss from discontinued operations, net of tax

 

 

 

 

 

 

 

(1

)

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

38

 

 

 

 

$

119

 

 

 

 

 

Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

0.35

 

 

 

 

$

1.12

 

 

 

 

 

Discontinued operations

 

 

 

 

 

 

 

(0.01

)

 

 

 

 

 

 

$

0.35

 

 

 

 

$

1.11

 

 

 

 

 

Diluted

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

0.35

 

 

 

 

$

1.11

 

 

 

 

 

Discontinued operations

 

 

 

 

 

 

 

(0.01

)

 

 

 

 

 

 

$

0.35

 

 

 

 

$

1.10

 

 

 

 

 

Weighted average shares and dilutive securities outstanding

(in thousands):

 

 

 

 

 

 

 

 

 

 

Basic

 

 

107,790

 

 

 

 

 

106,822

 

 

 

 

 

Diluted

 

 

108,750

 

 

 

 

 

108,569

 

 

 

 

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

(Dollars in millions except per share amounts)

 

Six Months Ended June 30,

 

 

2022

 

%

 

2021

 

%

 

Change

Net operating revenues

 

$

9,383

 

 

100.0

%

 

$

9,735

 

 

100.0

%

 

(3.6

) %

Grant income

 

 

100

 

 

1.1

%

 

 

50

 

 

0.5

%

 

100.0

%

Equity in earnings of unconsolidated affiliates

 

 

100

 

 

1.1

%

 

 

96

 

 

1.0

%

 

4.2

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

4,308

 

 

45.9

%

 

 

4,481

 

 

46.0

%

 

(3.9

) %

Supplies

 

 

1,596

 

 

17.0

%

 

 

1,663

 

 

17.1

%

 

(4.0

) %

Other operating expenses, net

 

 

1,948

 

 

20.8

%

 

 

2,126

 

 

21.8

%

 

(8.4

) %

Depreciation and amortization

 

 

419

 

 

4.5

%

 

 

445

 

 

4.6

%

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

73

 

 

0.8

%

 

 

40

 

 

0.4

%

 

 

Litigation and investigation costs

 

 

38

 

 

0.4

%

 

 

35

 

 

0.4

%

 

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

%

 

 

(15

)

 

(0.2

) %

 

 

Operating income

 

 

1,201

 

 

12.8

%

 

 

1,106

 

 

11.4

%

 

 

Interest expense

 

 

(449

)

 

 

 

 

(475

)

 

 

 

 

Other non-operating income, net

 

 

 

 

 

 

 

9

 

 

 

 

 

Loss from early extinguishment of debt

 

 

(109

)

 

 

 

 

(54

)

 

 

 

 

Income from continuing operations, before income taxes

 

 

643

 

 

 

 

 

586

 

 

 

 

 

Income tax expense

 

 

(185

)

 

 

 

 

(106

)

 

 

 

 

Income from continuing operations, before discontinued operations

 

 

458

 

 

 

 

 

480

 

 

 

 

 

Discontinued operations:

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

1

 

 

 

 

 

(1

)

 

 

 

 

Income (loss) from discontinued operations

 

 

1

 

 

 

 

 

(1

)

 

 

 

 

Net income

 

 

459

 

 

 

 

 

479

 

 

 

 

 

Less: Net income available to noncontrolling interests

 

 

281

 

 

 

 

 

263

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

178

 

 

 

 

$

216

 

 

 

 

 

Amounts available (attributable) to Tenet Healthcare Corporation common shareholders

 

 

 

 

 

 

 

 

 

 

Income from continuing operations, net of tax

 

$

177

 

 

 

 

$

217

 

 

 

 

 

Income (loss) from discontinued operations, net of tax

 

 

1

 

 

 

 

 

(1

)

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

178

 

 

 

 

$

216

 

 

 

 

 

Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.64

 

 

 

 

$

2.04

 

 

 

 

 

Discontinued operations

 

 

0.01

 

 

 

 

 

(0.01

)

 

 

 

 

 

 

$

1.65

 

 

 

 

$

2.03

 

 

 

 

 

Diluted

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.63

 

 

 

 

$

2.00

 

 

 

 

 

Discontinued operations

 

 

0.01

 

 

 

 

 

(0.01

)

 

 

 

 

 

 

$

1.64

 

 

 

 

$

1.99

 

 

 

 

 

Weighted average shares and dilutive securities outstanding

(in thousands):

 

 

 

 

 

 

 

 

 

 

Basic

 

 

107,636

 

 

 

 

 

106,566

 

 

 

 

 

Diluted

 

 

114,054

 

 

 

 

 

108,317

 

 

 

 

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

 

 

 

 

 

 

June 30,

 

December 31,

(Dollars in millions)

 

2022

 

2021

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

1,351

 

 

$

2,364

 

Accounts receivable

 

 

2,840

 

 

 

2,770

 

Inventories of supplies, at cost

 

 

387

 

 

 

384

 

Income tax receivable

 

 

18

 

 

 

 

Other current assets

 

 

1,468

 

 

 

1,557

 

Total current assets

 

 

6,064

 

 

 

7,075

 

Investments and other assets

 

 

3,297

 

 

 

3,254

 

Deferred income taxes

 

 

60

 

 

 

65

 

Property and equipment, at cost, less accumulated depreciation and amortization

 

 

6,259

 

 

 

6,427

 

Goodwill

 

 

9,479

 

 

 

9,261

 

Other intangible assets, at cost, less accumulated amortization

 

 

1,462

 

 

 

1,497

 

Total assets

 

$

26,621

 

 

$

27,579

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Current portion of long-term debt

 

$

125

 

 

$

135

 

Accounts payable

 

 

1,083

 

 

 

1,300

 

Accrued compensation and benefits

 

 

811

 

 

 

896

 

Professional and general liability reserves

 

 

272

 

 

 

254

 

Accrued interest payable

 

 

221

 

 

 

203

 

Contract liabilities

 

 

474

 

 

 

959

 

Other current liabilities

 

 

1,382

 

 

 

1,362

 

Total current liabilities

 

 

4,368

 

 

 

5,109

 

Long-term debt, net of current portion

 

 

14,947

 

 

 

15,511

 

Professional and general liability reserves

 

 

789

 

 

 

791

 

Defined benefit plan obligations

 

 

407

 

 

 

421

 

Deferred income taxes

 

 

161

 

 

 

36

 

Contract liabilities - long-term

 

 

14

 

 

 

15

 

Other long-term liabilities

 

 

1,824

 

 

 

1,439

 

Total liabilities

 

 

22,510

 

 

 

23,322

 

Commitments and contingencies

 

 

 

 

Redeemable noncontrolling interests in equity of consolidated subsidiaries

 

 

1,997

 

 

 

2,203

 

Equity:

 

 

 

 

Shareholders' equity:

 

 

 

 

Common stock

 

 

8

 

 

 

8

 

Additional paid-in capital

 

 

4,756

 

 

 

4,877

 

Accumulated other comprehensive loss

 

 

(231

)

 

 

(233

)

Accumulated deficit

 

 

(1,036

)

 

 

(1,214

)

Common stock in treasury, at cost

 

 

(2,410

)

 

 

(2,410

)

Total shareholders' equity

 

 

1,087

 

 

 

1,028

 

Noncontrolling interests

 

 

1,027

 

 

 

1,026

 

Total equity

 

 

2,114

 

 

 

2,054

 

Total liabilities and equity

 

$

26,621

 

 

$

27,579

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

 

 

 

Six Months Ended

(Dollars in millions)

 

June 30,

 

 

2022

 

2021

Net income

 

$

459

 

 

$

479

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

419

 

 

 

445

 

Deferred income tax expense

 

 

132

 

 

 

48

 

Stock-based compensation expense

 

 

34

 

 

 

30

 

Impairment and restructuring charges, and acquisition-related costs

 

 

73

 

 

 

40

 

Litigation and investigation costs

 

 

38

 

 

 

35

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

 

(15

)

Loss from early extinguishment of debt

 

 

109

 

 

 

54

 

Equity in earnings of unconsolidated affiliates, net of distributions received

 

 

18

 

 

 

10

 

Amortization of debt discount and debt issuance costs

 

 

15

 

 

 

17

 

Pre-tax (income) loss from discontinued operations

 

 

(1

)

 

 

1

 

Other items, net

 

 

(59

)

 

 

(22

)

Changes in cash from operating assets and liabilities:

 

 

 

 

Accounts receivable

 

 

(74

)

 

 

(101

)

Inventories and other current assets

 

 

173

 

 

 

56

 

Income taxes

 

 

(86

)

 

 

25

 

Accounts payable, accrued expenses, contract liabilities and other current liabilities

 

 

(764

)

 

 

(232

)

Other long-term liabilities

 

 

(41

)

 

 

(6

)

Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(98

)

 

 

(85

)

Net cash provided by operating activities

 

 

347

 

 

 

779

 

Cash flows from investing activities:

 

 

 

 

Purchases of property and equipment

 

 

(307

)

 

 

(243

)

Purchases of businesses or joint venture interests, net of cash acquired

 

 

(66

)

 

 

(64

)

Proceeds from sales of facilities and other assets

 

 

209

 

 

 

124

 

Proceeds from sales of marketable securities, long-term investments and other assets

 

 

9

 

 

 

18

 

Purchases of marketable securities and equity investments

 

 

(41

)

 

 

(19

)

Other items, net

 

 

(4

)

 

 

(11

)

Net cash used in investing activities

 

 

(200

)

 

 

(195

)

Cash flows from financing activities:

 

 

 

 

Repayments of other borrowings

 

 

(2,744

)

 

 

(2,012

)

Proceeds from other borrowings

 

 

2,013

 

 

 

1,409

 

Debt issuance costs

 

 

(24

)

 

 

(15

)

Distributions paid to noncontrolling interests

 

 

(310

)

 

 

(212

)

Proceeds from sale of noncontrolling interests

 

 

9

 

 

 

12

 

Purchases of noncontrolling interests

 

 

(29

)

 

 

(5

)

Medicare advances and grants received by unconsolidated affiliates, net of recoupment

 

 

 

 

 

6

 

Other items, net

 

 

(75

)

 

 

(19

)

Net cash used in financing activities

 

 

(1,160

)

 

 

(836

)

Net decrease in cash and cash equivalents

 

 

(1,013

)

 

 

(252

)

Cash and cash equivalents at beginning of period

 

 

2,364

 

 

 

2,446

 

Cash and cash equivalents at end of period

 

$

1,351

 

 

$

2,194

 

Supplemental disclosures:

 

 

 

 

Interest paid, net of capitalized interest

 

$

(416

)

 

$

(486

)

Income tax payments, net

 

$

(140

)

 

$

(34

)

TENET HEALTHCARE CORPORATION

SEGMENT REPORTING

(Unaudited)

 

 

 

Three Months Ended

 

Six Months Ended

(Dollars in millions)

 

June 30,

 

June 30,

 

 

2022

 

2021

 

2022

 

2021

Net operating revenues (1) :

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

771

 

 

$

664

 

 

$

1,509

 

 

$

1,310

 

Hospital Operations and other (prior to inter-segment eliminations)

 

 

3,645

 

 

 

4,095

 

 

 

7,443

 

 

 

8,042

 

Conifer

 

 

 

 

 

 

 

 

Tenet

 

 

111

 

 

 

124

 

 

 

226

 

 

 

246

 

Other clients

 

 

222

 

 

 

195

 

 

 

431

 

 

 

383

 

Total Conifer revenues

 

 

333

 

 

 

319

 

 

 

657

 

 

 

629

 

Inter-segment eliminations

 

 

(111

)

 

 

(124

)

 

 

(226

)

 

 

(246

)

Total

 

$

4,638

 

 

$

4,954

 

 

$

9,383

 

 

$

9,735

 

 

 

 

 

 

 

 

 

 

Equity in earnings of unconsolidated affiliates:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

52

 

 

$

49

 

 

$

94

 

 

$

87

 

Hospital Operations and other

 

 

2

 

 

 

5

 

 

 

6

 

 

 

9

 

Total

 

$

54

 

 

$

54

 

 

$

100

 

 

$

96

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA (including grant income):

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

319

 

 

$

295

 

 

$

601

 

 

$

552

 

Hospital Operations and other

 

 

431

 

 

 

449

 

 

 

945

 

 

 

883

 

Conifer

 

 

93

 

 

 

90

 

 

 

185

 

 

 

176

 

Total

 

$

843

 

 

$

834

 

 

$

1,731

 

 

$

1,611

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (including grant income):

 

 

 

 

 

 

 

 

Ambulatory Care

 

 

41.4

%

 

 

44.4

%

 

 

39.8

%

 

 

42.1

%

Hospital Operations and other

 

 

11.8

%

 

 

11.0

%

 

 

12.7

%

 

 

11.0

%

Conifer

 

 

27.9

%

 

 

28.2

%

 

 

28.2

%

 

 

28.0

%

Total

 

 

18.2

%

 

 

16.8

%

 

 

18.4

%

 

 

16.5

%

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (excluding grant income):

 

 

 

 

 

 

 

 

Ambulatory Care

 

 

41.1

%

 

 

41.4

%

 

 

39.6

%

 

 

39.6

%

Hospital Operations and other

 

 

9.3

%

 

 

10.9

%

 

 

11.4

%

 

 

10.6

%

Conifer

 

 

27.9

%

 

 

28.2

%

 

 

28.2

%

 

 

28.0

%

Total

 

 

16.1

%

 

 

16.4

%

 

 

17.4

%

 

 

15.9

%

 

 

 

 

 

 

 

 

 

Capital expenditures:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

19

 

 

$

27

 

 

$

40

 

 

$

35

 

Hospital Operations and other

 

 

130

 

 

 

90

 

 

 

262

 

 

 

200

 

Conifer

 

 

3

 

 

 

5

 

 

 

5

 

 

 

8

 

Total

 

$

152

 

 

$

122

 

 

$

307

 

 

$

243

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Net operating revenues include the impact of implicit price concessions and bad debts

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation

Common Shareholders to Adjusted Net Income Available from Continuing Operations

to Common Shareholders

(Unaudited)

 

(Dollars in millions except per share amounts)

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

 

 

2022

 

2021

 

2022

 

2021

Net income available to Tenet Healthcare Corporation common shareholders

 

$

38

 

 

$

119

 

 

$

178

 

 

$

216

 

Net income (loss) from discontinued operations

 

 

 

 

 

(1

)

 

 

1

 

 

 

(1

)

Net income from continuing operations

 

 

38

 

 

 

120

 

 

 

177

 

 

 

217

 

Less: Impairment and restructuring charges, and acquisition-related costs

 

 

(57

)

 

 

(20

)

 

 

(73

)

 

 

(40

)

Litigation and investigation costs

 

 

(18

)

 

 

(22

)

 

 

(38

)

 

 

(35

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

1

 

 

 

15

 

 

 

0

 

 

 

15

 

Loss from early extinguishment of debt

 

 

(66

)

 

 

(31

)

 

 

(109

)

 

 

(54

)

Tax impact of above items

 

 

15

 

 

 

5

 

 

 

21

 

 

 

18

 

Adjusted net income available from continuing operations to common shareholders

 

$

163

 

 

$

173

 

 

$

376

 

 

$

313

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share from continuing operations

 

$

0.35

 

 

$

1.11

 

 

$

1.63

 

 

$

2.00

 

Less: Impairment and restructuring charges, and acquisition-related costs

 

 

(0.52

)

 

 

(0.18

)

 

 

(0.64

)

 

 

(0.37

)

Litigation and investigation costs

 

 

(0.17

)

 

 

(0.20

)

 

 

(0.33

)

 

 

(0.32

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

0.01

 

 

 

0.14

 

 

 

 

 

 

0.14

 

Loss from early extinguishment of debt

 

 

(0.61

)

 

 

(0.29

)

 

 

(0.96

)

 

 

(0.50

)

Tax impact of above items

 

 

0.14

 

 

 

0.05

 

 

 

0.18

 

 

 

0.16

 

Adjusted diluted earnings per share from continuing operations

 

$

1.50

 

 

$

1.59

 

 

$

3.38

 

 

$

2.89

 

 

 

 

 

 

 

 

 

 

Weighted average basic shares outstanding (in thousands)

 

 

107,790

 

 

 

106,822

 

 

 

107,636

 

 

 

106,566

 

Weighted average dilutive shares outstanding (in thousands)

 

 

108,750

 

 

 

108,569

 

 

 

114,054

 

 

 

108,317

 

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation

Common Shareholders to Adjusted EBITDA

(Unaudited)

 

(Dollars in millions)

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

 

 

2022

 

2021

 

2022

 

2021

Net income available to Tenet Healthcare Corporation common shareholders

 

$

38

 

 

$

119

 

 

$

178

 

 

$

216

 

Less: Net income available to noncontrolling interests

 

 

(141

)

 

 

(138

)

 

 

(281

)

 

 

(263

)

Income (loss) from discontinued operations, net of tax

 

 

 

 

 

(1

)

 

 

1

 

 

 

(1

)

Income from continuing operations

 

 

179

 

 

 

258

 

 

 

458

 

 

 

480

 

Income tax expense

 

 

(86

)

 

 

(61

)

 

 

(185

)

 

 

(106

)

Loss from early extinguishment of debt

 

 

(66

)

 

 

(31

)

 

 

(109

)

 

 

(54

)

Other non-operating income (expense), net

 

 

 

 

 

(1

)

 

 

 

 

 

9

 

Interest expense

 

 

(222

)

 

 

(235

)

 

 

(449

)

 

 

(475

)

Operating income

 

 

553

 

 

 

586

 

 

 

1,201

 

 

 

1,106

 

Litigation and investigation costs

 

 

(18

)

 

 

(22

)

 

 

(38

)

 

 

(35

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

1

 

 

 

15

 

 

 

 

 

 

15

 

Impairment and restructuring charges, and acquisition-related costs

 

 

(57

)

 

 

(20

)

 

 

(73

)

 

 

(40

)

Depreciation and amortization

 

 

(216

)

 

 

(221

)

 

 

(419

)

 

 

(445

)

Adjusted EBITDA

 

$

843

 

 

$

834

 

 

$

1,731

 

 

$

1,611

 

 

 

 

 

 

 

 

 

 

Net operating revenues

 

$

4,638

 

 

$

4,954

 

 

$

9,383

 

 

$

9,735

 

 

 

 

 

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues

 

 

0.8

%

 

 

2.4

%

 

 

1.9

%

 

 

2.2

%

 

 

 

 

 

 

 

 

 

Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)

 

 

18.2

%

 

 

16.8

%

 

 

18.4

%

 

 

16.5

%

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow from Continuing Operations

(Unaudited)

 

(Dollars in millions)

 

2022

 

 

Q2

 

YTD

Net cash provided by operating activities

 

$

119

 

 

$

347

 

Purchases of property and equipment

 

 

(152

)

 

 

(307

)

Free cash flow

 

 

(33

)

 

 

40

 

Add back: Medicare Advance Repayments

 

 

281

 

 

 

475

 

Free cash flow, excluding repayment of Medicare Advances

 

$

248

 

 

$

515

 

 

 

 

 

 

Net cash used in investing activities

 

$

(140

)

 

$

(200

)

Net cash used in financing activities

 

$

(33

)

 

$

(1,160

)

 

 

 

 

 

Net cash provided by operating activities

 

$

119

 

 

$

347

 

Less: Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(42

)

 

 

(98

)

Adjusted net cash provided by operating activities from continuing operations

 

 

161

 

 

 

445

 

Purchases of property and equipment

 

 

(152

)

 

 

(307

)

Adjusted free cash flow – continuing operations

 

 

9

 

 

 

138

 

Add back: Medicare Advance Repayments

 

 

281

 

 

 

475

 

Adjusted free cash flow – continuing operations, excluding repayments of Medicare Advances

 

$

290

 

 

$

613

 

(Dollars in millions)

 

2021

 

 

Q2

 

YTD

Net cash provided by operating activities

 

$

245

 

 

$

779

 

Purchases of property and equipment

 

 

(122

)

 

 

(243

)

Free cash flow

 

 

123

 

 

 

536

 

Add back: Medicare Advance Repayments

 

 

152

 

 

 

152

 

Free cash flow, excluding repayment of Medicare Advances

 

$

275

 

 

$

688

 

 

 

 

 

 

Net cash used in investing activities